Phase II Study of a Reduced-toxicity " Submyeloablative " Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
Inclusion Criteria:
- Patients affiliated to a social security reimbursement system
- Adults (men or women) aged between 18 and 65 years
- Negative test for pregnancy
- ECOG 0-1 or Karnofsky Index ≥ 70%
- Availability of an HLA-identical sibling donor, or an HLA-matched unrelated donor
(10/10 HLA compatibility in A, B, C, DRB1, DQB1 (a single allelic mismatch at the
level of Cw can be accepted)
- Life expectancy > 6 months
- Signed informed consent
- Diagnosis of an hematological malignancy that is considered to be eligible for an
allogeneic stem cell transplantation
Exclusion Criteria:
- Pregnant woman or not willing to take effective contraception
- Classical contra-indications to the allogeneic stem cell transplantation procedure
- Any contra-indication to the use of the drugs contained within the conditioning
regimen according to the summary of product characteristics
- Patients aged < 50 years and deemed to be eligible for a "standard" or conventional
myeloablative conditioning regimen
- An HLA-matched sibling donor who has a contra-indication for stem cell mobilization
and collection
- History of uncontrolled psychiatric condition
- Patients who have participated to another trial testing an experimental drug within
one month prior to inclusion in this protocol.